Japan

Three $1bn+ alliances were penned in February, and one exceeded $2bn.

Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.

Select Indian drug manufacturers have missed some analyst estimates while Japanese firms continue in their efforts to leave the country’s generic drug supply crisis in the past.

Generics Bulletin reviews the latest regulatory developments across the world.

While Japan looks set to further improve policies to support ventures and ease market entry this year, these will contrast with ongoing reimbursement price controls.

As efforts to improve diversity in clinical trials gain momentum globally, regulators in the UK, the EU, Canada, Australia and Japan were asked about their efforts to support representative enrolment. 

Celebrating its first birthday as a transformed and integrated company, Biocon casts a wider net for its ustekinumab biosimilar.

This year, regulators questioned the US interchangeability designation and the need for comparative efficacy trials, while finding ways to promote biosimilar development and accessibility. Will this momentum continue in 2025? Generics Bulletin spoke to experts from across the industry to hear their views.

Medtech innovators in the APAC region have in recent years seen a slowdown in investment following a combination of rising costs, supply chain challenges and inflationary pressures. But there is light at the end of the tunnel, says MedTech Innovator APAC leader Fredrik Nyberg.

The divestment decision comes years after it slimmed down amid challenges in the Japanese generic market.